Full-Time
Quality Control Instrumentation Specialist
Updated on 8/1/2026
Fujifilm
501-1,000 employees
Global precision manufacturer for healthcare
No salary listed
Holly Springs, NC, USA
In Person
 Lab & Research (1) |
|---|
Get referred to Fujifilm
See people who can refer or advise you
- Working knowledge and experience with Microsoft Office products, including Outlook, Word, Excel, and PowerPoint.
- Demonstrated ability to work cross-functionally and develop and maintain strong business partner relationships.
- Thorough understanding of pharmaceutical and biotech testing.
- Proven ability to understand and implement data integrity standards and regulations.
- Proven ability to conduct investigations and write deviations and corrective and preventative actions.
- Superior technical writing and problem-solving skills.
- Ability to effectively communicate and function in a fast-paced, highly technical environment.
- Bachelor’s degree in a relevant scientific discipline, preferably Chemistry, Biochemistry, Microbiology, Biology, or Life Sciences.
- Zero to three years of laboratory experience.
- Prior hands-on experience with analytical instrumentation associated with UPLC/HPLC, capillary electrophoresis or imaged capillary isoelectric focusing, gel electrophoresis or Western blot, plate readers, qPCR, spectrophotometry, and mass spectrometry.
- Ability to discern audible cues.
- Ability to inspect or perform a task with 20/20 corrected vision, including distinguishing color.
- Ability to stand for up to 60 minutes and sit for up to 60 minutes.
- Ability to conduct activities using repetitive motions involving the wrists, hands, and/or fingers.
- Ability to move objects weighing up to 10 pounds.
- Ability to bend, push or pull, reach to retrieve materials from 18 inches to 60 inches in height, and use twisting motions.
- Ability to work in small and/or enclosed spaces and at heights greater than four feet.
- Support the qualification, routine operation, maintenance, and decommissioning of quality control analytical instruments.
- Ensure quality control equipment and instruments adhere to regulatory guidelines and site policies.
- Assist in drafting and reviewing standard operating procedures, technical reports, user requirements, and maintenance documentation.
- Participate in data integrity initiatives related to analytical instruments.
- Help recommend appropriate user roles and privileges for data integrity and assist in writing operation instructions and preventative maintenance plans.
- Coordinate with vendors for maintenance activities on quality control instruments.
- Complete routine periodic reviews of quality control instruments and their control software.
- Identify, report, and follow up on excursions and deviations and assist with corrective and preventative actions.
- Provide support and guidance to stakeholders, including end users, on quality control analytical instrumentation.
- Work cross-functionally with all end users as needed.
- Good manufacturing practice laboratory experience.
- Experience with Kneat software.
- Experience qualifying analytical instruments.
Fujifilm Corporation is the main operating and manufacturing arm of the Fujifilm group, applying its precision chemistry, nanotechnology, and optical engineering to deep-tech and life sciences. It runs Bio CDMO facilities that manufacture biopharmaceuticals and vaccines, makes advanced materials like photoresists and chemical slurries for semiconductors, and develops AI-powered diagnostic imaging devices, endoscopes, and ultrasound systems, while also selling INSTAX cameras and X-Series products. It differentiates itself by applying a long history of precision manufacturing at scale across life sciences, materials, and medical devices rather than focusing on a single niche. Its goal is to turn strategic capabilities into tangible products that advance healthcare, electronics manufacturing, and imaging, maintaining leadership in precision manufacturing and applied science worldwide.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Tokyo, Japan
Founded
1934
Get referred to Fujifilm
See people who can refer or advise you
Simplify's Take
What believers are saying
- Healthcare, electronics, and imaging create multiple growth engines across end markets.
- Bio-CDMO demand supports long-cycle revenue from pharma and vaccine manufacturing clients.
- AI-enabled maintenance software can improve service efficiency and protect printer margins.
What critics are saying
- Semiconductor and display materials face cyclic demand swings and customer concentration.
- Imaging growth depends on filling the XF telephoto gap before competitors gain share.
- Business Innovation faces software imitation pressure from copier and office-equipment rivals.
What makes Fujifilm unique
- Built from photographic film chemistry into healthcare, electronics, and imaging businesses.
- Operates Bio-CDMO, semiconductor materials, and medical devices under one industrial platform.
- Combines consumer brands like INSTAX with high-value B2B manufacturing capabilities.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Paid Vacation
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -43%1 year growth
↓ -43%2 year growth
↓ -43%Harry Singh exits Reacon, rejoins FUJIFILM BI aust. 28 July, 2026 Former Reacon Australia CEO Harry Singh has stepped down from his role following the completion of a planned leadership transition at the company. As a result, Singh has now rejoined FUJIFILM Business Innovation (BI) Australia as national sales manager within its Graphic Communications business. In the established role, Singh assumes its responsibilities as part of a planned transition. He will report directly to FUJIFILM BI Australia Graphic Communications general manager Steve Fisher. In this national role, Singh's primary responsibility is leading and managing the sales specialist team within FUJIFILM BI Australia's direct channel. He will focus on driving sustainable business growth, supporting sales performance and developing strategic opportunities across the business. His scope will also involve working closely with FUJIFILM BI Australia's account management, technical, and service teams to understand customers' production, workflow, and application requirements, and to connect those needs with relevant technology and specialist support. A key priority will be strengthening collaboration across FUJIFILM BI Australia's commercial, specialist, technical and service teams, helping customers access the right expertise throughout their technology investment journey. Singh will also focus on developing the national sales specialist team and ensuring its expertise contributes to stronger customer outcomes and long-term business growth. Singh previously worked with FUJIFILM BI Australia in the Graphic Communications business before joining Reacon Group, where he held senior sales and leadership responsibilities, including head of sales and, most recently, CEO. Fisher said, "To say we are delighted to welcome Harry back to FUJIFILM BI Australia is an understatement. He is well known and highly respected across the Graphic Communications industry, and brings strong technical knowledge, commercial experience, and established customer relationships. "Importantly, Harry returns with an even broader perspective from his time on the customer side of the industry. He has a deep understanding of the investment decisions and operational pressures print businesses manage every day. That experience, combined with our commitment to delivering an exceptional end-to-end customer experience, makes him ideally suited to lead our national sales specialist team. "As we continue to focus on maximising value for customers - including through intelligent automation, specialty toner capabilities, and exceptional print quality - Harry's leadership will strengthen the support we provide to our salespeople and customers. It will also help us identify strategic opportunities and drive sustainable growth." Singh said, "I'm incredibly excited to be rejoining FUJIFILM Business Innovation Australia and working with Steve and our highly talented Graphic Communications team. "FUJIFILM BI Australia has a highly regarded portfolio, with a strong reputation for exceptional print quality, intelligent automation, and innovative capabilities. The opportunity to work with this technology, an experienced team, and customers across the industry made returning to the business an easy decision. "I return with an even greater appreciation of the customer experience and the factors Australian print businesses consider when investing in technology. "There is a real opportunity to draw on the breadth of expertise across our industry businesses to better understand and serve the evolving needs of print providers. Above all, we want to work alongside our customers as a long-term partner and contribute to the continued success of the Australian print industry." Reflecting on the journey at Reacon, Singh said the achievements belong to the people across the business. "The past 12 months have demonstrated what can be achieved when talented people work together with a shared purpose. Significant change is never easy, but our teams embraced the challenge and remained focused on delivering for customers while building a stronger organisation for the future," he said. "It has been a privilege to be part of this chapter in the company's history. I am incredibly proud of what the team has accomplished together and thankful for the support, commitment, and professionalism shown throughout the process." Vik Gulati, who has stepped back into the CEO role at Reacon, thanked Singh for his efforts. "Thank you, Harry Singh. The work you've done over the past 12 months has set Reacon up for exactly the kind of future we've been building towards. You leave the business in a far stronger position than you found it, and that's no small thing. The platform you've built is exactly what we needed to grow from. It's been a genuine pleasure - wishing you every success in what comes next," he said. Reacon recently announced the appointment of Vin Gulati as its new sales and growth lead. The company also installed Australia's first FUJIFILM Jet Press 1160CF continuous feed inkjet press Between May and June 2024, delivering offset quality output at digital speed.
Fujifilm business innovation achieves horizontal plastic recycling. FUJIFILM Business Innovation Corp. and Teijin Limited have jointly achieved horizontal closed-loop recycling for the exterior covers of multifunction printers. The newly developed process allows collected end-of-life printer covers to be recycled into new front covers that meet strict aesthetic and physical standards. FUJIFILM Business Innovation has always operated a closed-loop system to remanufacture printers. The company traditionally reused parts by cleaning them and applying a blasting process. Front exterior covers present a specific challenge because they require high visual quality. Covers with severe scratches could not undergo standard reuse processes and required replacement with newly manufactured parts. To keep these plastics in a continuous loop, the two companies developed a tailored recycling method. FUJIFILM Business Innovation uses a wet crushing technique, which washes the plastic components while crushing them to minimise contamination from foreign materials. Teijin then applies its advanced compounding technology to adjust the colour and restore the physical properties of the degraded plastic. This collaboration results in a material containing 80 percent recycled content that mirrors the appearance and durability of virgin plastic. The recycled plastic is currently applied to the remanufactured ApeosPort VII C R and ApeosPort C R series. This advancement is a shift from downcycling to horizontal recycling.
EXCLUSIVE: this is Fujifilm's second XF lens coming in september. Then, in June, - from lovely Sardinia - Fujirumors told you that one of the two lenses would be the successor to this lens here. Well, today Fujirumors can give you more details about what the second lens will be. According to its trusted sources, Fujifilm will launch an XF telephoto prime lens along with the Fujifilm X-T6, closing what the top Fujifilm manager called their biggest gap in the lens lineup. I am working on the details, but I need to sort out some conflicting reports before I can share additional - and accurate - details. So give me just a little bit more time. In the meantime, I also revisited the famous list of 10 lenses Fujifilm said were "under consideration." Notably, it doesn't include a single XF telephoto prime. That's yet another reminder that, contrary to what some claimed, this was never an official Fujifilm roadmap. Here on FujiRumors, Fujirumors warned you from the very beginning not to treat that list as one. And just out of curiosity, I looked back at pretty much all the telephoto lenses Fujifilm has patented so far, which are: But again: as Fujirumors explained in this article, patents mean close to nothing. A while ago Fujirumors looked at 67 Fujifilm patents and noticed not a single one was spotted before it materialized into a real product. And yet, just for fun, I was wondering, out of all those patents, which is the one you'd like to get. Feel free to vote the survey below. I'd Like the Following Fujinon Telephoto Prime Lens **This post contains affiliate links and I will be compensated if you make a purchase after clicking through my links. As an Amazon Associate I earn from qualifying purchases
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT(TM). * Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell's pivotal Phase 3 study and commercial scalability potential * Bria-IMT is currently being evaluated in Bria-Cell's ongoing pivotal Phase 3 study in metastatic breast cancer PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces a manufacturing arrangement with FUJIFILM Biotechnologies California, a leading contract development and manufacturing organization (CDMO) specializing in cell therapies, to support the ongoing pivotal Phase 3 clinical development and potential future commercial supply of BriaCell's lead clinical candidate, Bria-IMT, an off-the-shelf allogenic cell therapy. Bria-IMT is currently being evaluated in BriaCell's pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). "Securing manufacturing capacity with Fujifilm, a global leader in cell therapy manufacturing, represents a key milestone in our Bria-IMT development and potential commercialization strategy as we work toward our goal of bringing this novel immunotherapy candidate to patients with metastatic breast cancer," said William V. Williams, MD, President and Chief Executive Officer of BriaCell. About BriaCell Therapeutics Corp. BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/. About FUJIFILM Biotechnologies California FUJIFILM Biotechnologies California, a subsidiary of FUJIFILM Corporation, specializes in developing and manufacturing cell-based therapeutics. Located in Thousand Oaks, California, the company operates a state-of-the-art cell therapy manufacturing facility featuring cGMP production suites, quality control and development laboratories, and product storage and distribution capabilities. These facilities support both autologous and allogeneic cell therapy manufacturing while meeting global regulatory standards for advanced therapies and medicinal products. With its highly skilled and experienced workforce and regulatory agency approved manufacturing capabilities, FUJIFILM Biotechnologies California is shaping the future of medicine through the advanced production of cell therapies. The company leverages the global network and end-to-end CDMO capabilities of the Fujifilm Life Sciences Group to provide solutions that support complex cell therapy development and manufacturing. About FUJIFILM FUJIFILM Americas is the regional headquarters for the Americas. It is comprised of 20 group companies across North and Latin America that are engaged in the research, development, manufacture, sale and service of Fujifilm products and services. The company's portfolio represents a broad spectrum of industries including medical and life sciences, electronic materials, chemical, graphic arts, information systems, industrial products, broadcast, data storage, and photography. For more information, please visit: https://www.fujifilm.com/us/en/about/region. Safe Harbor This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the manufacturing arrangement with FUJIFILM Biotechnologies California, the availability of manufacturing capacity to support the remainder of BriaCell's ongoing pivotal Phase 3 study, the potential for future commercial-scale manufacturing of Bria-IMT, the continued development and commercialization of Bria-IMT, and the evaluation of Bria-IMT in BriaCell's ongoing pivotal Phase 3 study in advanced metastatic breast cancer, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law. Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release. Contact Information Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 [email protected] Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Annual Fujifilm Healthcare Europe Distributor Meeting 2026. Endoscopiki Sa had the pleasure of participating in the Annual Fujifilm Healthcare Europe Distributor Meeting 2026, held in Zandvoort, the Netherlands. As Fujifilm's trusted partner in Greece and Cyprus since 1979, it was a valuable opportunity to reconnect with distribution partners from across Europe, exchange knowledge, discuss market developments, and strengthen its collaboration in delivering innovative healthcare solutions. Alongside the business sessions, participants enjoyed a memorable visit to the iconic Circuit Zandvoort, home of the Dutch Formula 1 Grand Prix, adding a unique experience to an already inspiring event. Endoscopiki Sa would like to thank the Fujifilm Healthcare Europe team for the excellent organization and warm hospitality. Endoscopiki Sa look forward to continuing its successful collaboration and building on a partnership that has proudly lasted for more than four decades.